All Authorea-powered sites will be offline 6am-10am EDT Tuesday 11 June
for Essential Maintenance. We apologise for any inconvenience.

Background: The prevalence of hypertrophic cardiomyopathy (HCM) can be silent and can present with sudden death as the first manifestation of this disease. The goal of this study was to evaluate any association between reported physical symptoms with the presence of suspected HCM. Method: The Anthony Bates Foundation has been performing screening echocardiography across the United States for the prevention of sudden death since 2001. A total of 4,120 subjects between the ages of 6 and 79 underwent echocardiographic screening. We evaluated any association between any symptoms and suspected HCM defined as any left ventricular wall thickness ≥ 15 mm. Results: The total prevalence of suspected HCM in the entire study population was 1.1%. The presence of physical symptoms were not associated with HCM (chest pain in 4.3% of participant with HCM vs. 9.9% of the control, p=0.19, palpitation in 4.3% of participant with HCM vs. 7.3% of the control., p=0.41, shortness of breath in 6.4% of participant with HCM vs. 11.7% of the control., p=0.26, lightheadedness in 4.3% of participant with HCM vs. 13.1% of the control., p=0.07, ankle swelling in 2.1% of participant with HCM vs. 4.0% of the control., p=0.52, dizziness in 8.5% of participant with HCM vs. 12.2% of the control., p=0.44). Conclusion: Echocardiographic presence of suspected HCM is not associated with a higher prevalence of physical symptoms in the participants undergoing screening echocardiography. This finding confirmed that HCM can be asymptomatic in many patients and a questionnaire cannot distinguish the HCM population from a control group.